Welcome • User Guide
ToS • Privacy • Canary
Donate • Bugs • License

©2025 Poal.co

Scientist Admits to Stealing Monoclonal Antibody Research for Chinese Communist Party Pennsylvania scientist pleads guilty to stealing medical research for CCP pharma company

A Pennsylvania scientist has pleaded guilty to stealing monoclonal antibody research for the Chinese Communist Party (CCP), according to reports.Lucy Xi, 44, of Malvern, Pennsylvania, admitted to stealing trade secrets for a CCP-run pharmaceutical company.According to the Eastern District of Pennsylvania, she was able to acquire the secret research after forming fraudulent cancer research and drug company which she used to store the stolen information.The suspect pleaded guilty to stealing trade secrets from GlaxoSmithKline (GSK), a large multinational pharmaceutical company.The precious medical research was then given to Renopharma, a Chinese Communist Party-controlled pharmaceutical company.

Scientist Admits to Stealing Monoclonal Antibody Research for Chinese Communist Party Pennsylvania scientist pleads guilty to stealing medical research for CCP pharma company A Pennsylvania scientist has pleaded guilty to stealing monoclonal antibody research for the Chinese Communist Party (CCP), according to reports.Lucy Xi, 44, of Malvern, Pennsylvania, admitted to stealing trade secrets for a CCP-run pharmaceutical company.According to the Eastern District of Pennsylvania, she was able to acquire the secret research after forming fraudulent cancer research and drug company which she used to store the stolen information.The suspect pleaded guilty to stealing trade secrets from GlaxoSmithKline (GSK), a large multinational pharmaceutical company.The precious medical research was then given to Renopharma, a Chinese Communist Party-controlled pharmaceutical company. [Read More](https://neonnettle.com/news/17951-scientist-admits-to-stealing-monoclonal-antibody-research-for-chinese-communist-party)

(post is archived)

You are currently inside a comment thread.
Click here to see all the comments (2).